Doubts grow over GlaxoSmithKline's $6 bln capital return plan
May 01, 2015 at 07:03 AM EDT
LONDON, May 1 (Reuters) - GlaxoSmithKline may ditch a plan to return 4 billion pounds ($6.1 billion) to investors, some analysts believe, as the drugmaker prepares to set out its vision for the reshaped group and a new chairman takes the helm.
